Among the hypoglycemic agents that increase the chance of HF, we highlight the thiazolidinediones (RECORD study - rosiglitazone; and PROactive - pioglitazone)59,60 and a dipeptidyl peptidase-4 inhibitor (DPP-4i) - the saxagliptin (SAVOR-TIMI 53).61 In the studies RECORD and SAVOR-TIMI, patients with HF also had higher subsequent mortality rates. This evidence concerns the gene DPP4 and hydrops fetalis.